STOCK TITAN

MAIA Biotechnology, Inc. - $MAIA STOCK NEWS

Welcome to our dedicated page for MAIA Biotechnology news (Ticker: $MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MAIA Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MAIA Biotechnology's position in the market.

Rhea-AI Summary
MAIA Biotechnology to present latest findings on telomere-targeting immunotherapies at International Biochemistry Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
conferences
-
Rhea-AI Summary
MAIA Biotechnology announces promising results for THIO treatment in Diffuse Intrinsic Pontine Glioma (DIPG) at the Society for Neuro-Oncology's conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology announces dosing of 49 patients in Phase 2 clinical trial for lung cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
Rhea-AI Summary
MAIA Biotechnology announces highly potent anticancer activity of THIO in gliomas
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. has received FDA clearance for its Investigational New Drug application for THIO to be evaluated in the U.S. as part of THIO-101 global phase 2 clinical study in NSCLC patients. This represents a significant milestone in the development of THIO as a telomere targeting agent for advanced NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces $800,000 share repurchase program, reflecting confidence in market opportunity and long-term growth strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.8%
Tags
buyback
Rhea-AI Summary
MAIA Biotechnology reports positive preliminary results for THIO-101 phase 2 trial and expands telomere-targeting molecule program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.44%
Tags
MAIA Biotechnology, Inc.

NYSE:MAIA

MAIA Rankings

MAIA Stock Data

58.45M
14.55M
21.43%
3.9%
4.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CHICAGO

About MAIA

maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru